- Home
- ADCT
ADCT
ADC Therapeutics SA
as 05-17-2024 4:00pm EST
$.
+$.
+.%
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
| Founded: | N/A | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 356.1M | IPO Year: | 2020 |
| Target Price: | $7.00 | AVG Volume (30 days): | 592.5K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $6.04 | Next Earning Date: | 05-06-2024 |
| Revenue: | $68,619,000 | Revenue Growth: | -62.38% |
| Revenue Growth (this year): | 18.34% | Revenue Growth (next year): | 13.81% |
Share on Social Networks:
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Simply Wall St.
9 days ago
ADC Therapeutics First Quarter 2024 Earnings: In Line With Expectations
GuruFocus.com
10 days ago
Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)
GlobeNewswire
11 days ago
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
Simply Wall St.
11 days ago
ADC Therapeutics SA (NYSE:ADCT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Insider Monkey
13 days ago
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
MT Newswires
13 days ago
HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating
MT Newswires
14 days ago